您好,欢迎来到上海士研管理咨询有限公司
产业峰会 演讲局 专家智库服务 峰会活动服务 整合营销服务
  • 产业峰会:
    以专业团队对产业和市场客观详实地调研为前提,拥有战略性、系统性、全球性的基因,汇集了领导者关注的热点话题与领袖代表,为您提供“一站式”的对话、分享、社交平台!
  • 演讲局:
    致力于为全球企业和机构提供主题演讲家、高管大师班、董事会顾问,每项服务都提供了一种更深入、更具互动性的体验,尤其是针对较小的精选受众和关键个人。我们拥有最具影响力的商业领袖和顶级专家的资源,他们是各自领域的最杰出的代表。我们的团队由经验丰富的演讲和活动经理组成,我们注重建立长期而深入的伙伴关系。
  • 专家智库服务:
    中国领先的行业专家知识信息服务供应商,为需要专业洞见的商业决策者匹配具有一手经验的行业专家,助力他们以更加明确的目标和坚定的信心做出决策。我们有60万余名专家顾问遍布二十多个行业,而且每天还在增加!
  • 峰会活动服务:
    致力于成为全球最专业的产业峰会活动提供商,为企业和机构的产业性峰会活动提供一站式专业服务,包括调研策划、定制邀请、营销推广、运营组织、项目管理、直播与数字化会议等,每项服务都由经验丰富的专业团队匹配长期沉淀的产业资源予以卓越执行,我们注重建立长期而深入的伙伴关系。
  • 整合营销服务:
    致力于成为全球领先的2B营销服务机构,聚焦产业高端活动、内容、渠道的建设与沉淀,为客户提供一站式整合营销解决方案,助力企业线上线下获客与品牌筑造。我们深信专业团队匹配产业资源带来卓越执行,我们注重建立长期而深入的伙伴关系。
嘉宾信息
发布时间: 2019 - 07 - 10
点击次数: 0
所属职位: Head of Research Beyond Borders China
所属公司: 勃林格殷格翰
个人简介:
Weiyi Zhang is currently the Sr. Director and head of external innovation China at Boehringer Ingelheim, and she is responsible for setting up collaborations in China for research functions at BI. Weiyi gained her bachelor degree in Biology at Xiamen University in 2001. She joined international Max-Planck research school in chemical biology in 2003 and studied function of olfactory G-protein coupled receptor in non-olfactory tissues. She obtained her Ph.D in cell biology from Ruhr-University Bochum in 2007. Since 2008, Weiyi started postdoc training in functional study of orphan GPCRs in central neural system at both National Institute of Biological Sciences and the University of Hong Kong.Before joining Boehringer Ingelheim, Weiyi has led a cell biology group at BioDuro-PPD in Beijing since 2009, focusing on cell-based assays and integrated early drug discovery programs for various pharmaceutical companies. Then she has led the monoclonal antibody research group at Bio-Rad Laboratory in Shanghai from 2012 to 2013. From 2013 to 2016, Weiyi was the associate director at Innovation Center China of Global Drug Discovery at Bayer Healthcare.
发布时间: 2019 - 07 - 10
点击次数: 0
所属职位: 首席财务官
所属公司: 天境生物科技(上海)有限公司
个人简介:
As the Chief Financial Officer, Jielun Zhu, MBA, CFA, is in charge of the overall financial strategy and management, capital investment, corporate finance and investor relations. He is a veteran and expert in the finance industry, with over 11 years of experience in investment banking. From December 2015 to July 2018, prior to joining I-Mab, he served as a managing director and Asia Head of Healthcare Investment Banking and Capital Markets in Hong Kong for Jefferies Group LLC, a global full-service investment bank with a strong focus in healthcare.At Jefferies, he advised many biotechnology and healthcare clients globally on IPOs and other financings, as well as mergers and acquisitions. From August 2008 to September 2015, he worked for the Deutsche Bank Group in its Hong Kong office. He occupied a succession of positions, with the last one being Director in the Corporate Finance Division, which entailed working with leading clients in the healthcare and other sectors in Greater China. From July 2007 to July 2008, he was an investment banker in Hong Kong with UBS AG. Before investment banking, Mr. Zhu was a strategy consultant in Boston focused on serving clients in the US pharmaceutical and biotechnology industry.Mr. Zhu earned his M.B.A. from the Harvard Business School with distinction in June 2007 and his Bachelor of Arts degree with honors in mathematics-economics from Wesleyan University. He is also a CFA charter holder.
发布时间: 2019 - 07 - 10
点击次数: 0
所属职位: 首席运营官
所属公司: 北京盛诺基医药科技有限公司
个人简介:
Dr. Wang is currently Chief Operating Office of Beijing Shenogen Pharma Group Ltd. And previously the President of Novo Nordisk Research Center China, the first R&D center set up by a global pharmaceutical company in China. Baoping received a BS degree in Applied Chemistry from Shanghai Jiao Tong University in 1982, and a PhD in Genetics from University of Minnesota in 1990. He did his postdoc research at Harvard Medical School where he then served sequentially as an Instructor and Assistant Professor. His research area focused on molecular and cellular immunology. Baoping joined industry when he returned China in 1998 to head a health care group in Novo Nordisk China R&D center. In 2001, Novo Nordisk established a new R&D center based on the health care group, Baoping was the head of the center since its founding. From April 2007, Baoping also served as a Vice President of Novo Nordisk R&D, and from January 2011 through July 2018, as President of Novo Nordisk Research Center China. He has joined Beijing Shenogen Pharma Group Ltd. as Chief Operating Office from August 2018. 教育背景 1978-1982  上海交通大学应用化学系 高分子材料专业 获工学学士学位1983-1990   美国明尼苏达大学生物学院遗传与细胞生物系分子免疫学专业 获博士学位 职业经历 1990-1991 哈佛医学院病理系及Dana Farber癌症研究所分子免疫学室 博士后1991-1995哈佛医学院医疗系及 Beth Israel医院免疫学室 博士后1995-1997  哈佛医学院医疗系及 Beth Israel医院免疫学室 讲师1998.1-1998.8  哈佛医学院医疗系及 Beth Israel医院免疫学室 助理教授1998.8-2001.8  诺和诺德(中国)研究发展中心 助理总监2001.9-2007.3 诺和诺德中国研究发展中心研究总监2007.4-2011.1  诺和诺德中国研发中心总经理,诺和诺德研发部付总裁20011.1-2018.7  诺和诺德中国研发中心总裁20018.8-    北京盛诺基医药科技有限公司,首席运营官
发布时间: 2019 - 07 - 10
点击次数: 0
所属职位: 副总裁
所属公司: 上海恒润达生生物科技有限公司
个人简介:
宋晓东博士现任上海恒润达生生物科技有限公司副总经理,负责公司研发,临床,专利,注册,生产,质量,业务拓展,项目管理等部门的工作。宋博士目前正带领团队在国内,美国,欧洲和中东地区积极准备CAR-T临床试验的启动工作,为把自主研发的CAR-T推向世界和促进一带一路的技术合作做出应有的贡献。 在加入恒润达生之前,宋博士曾任美国强生公司全球法规注册事务部总监并在强生工作5年。他是强化亚太地区药品生产领导团队的成员之一。宋博士负责监督和支持强生公司在中国以及亚太地区药物研发,药品生产和注册申报中的业务。宋博士也曾担任过RDPAC药学理事会主席。他一直积极参加与中国药品监管和法规注册相关的活动,并与国家药品监督管理局以及各行业协会合作共同促进中国医药行业法规的健全和发展。 在加入强生公司之前,宋博士曾在美国辉瑞制药公司工作15年。他曾在辉瑞公司全球药物研发中心,全球药品生产总部和全球仿制药调查部门任职。宋博士曾担任辉瑞全球仿制辉瑞药品的专利侵权调查以及质量评价工作部门的负责人。他还创立了辉瑞制药公司辅料化学协议并担任首届主席,领导与辅料相关的研究和调查,并解决药物在研发和生产阶段由于药物和辅料相互作用带来的挑战。宋博士也曾是辉瑞全球药物研发中心新药剂型研发团队的主要成员。 在加入辉瑞公司之前,宋博士在美国康涅狄格州的奥林公司接受生物化学博士后训练。他于1996年在美国路易斯安纳大学获得药物化学博士学位,于1990年在中国科学技术大学获得分析化学硕士学位,于1987年在浙江工业大学获得分析化学学士学位。
75页次7/19首页上一页...  234567891011...下一页尾页
微信公众号
领导者网络APP
友情链接
Copyright ©2005 - 2017上海士研管理咨询有限公司
犀牛云提供企业云服务